Phase 2 N=66 The Prevention of Hypotension After Epidural Analgesia After Major Surgery
Hypotension · Pain
Primary: Changes Between the 3 Groups Assessed by Blood Pressure Measurement — 5; 2; 3; 10 Participants — p=0.165
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=94 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Basal Cell Carcinoma · Skin Cancer · Cancer of the Skin, Basal Cell
Primary: Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events — 0 Participants
Phase 2 N=9 Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
Short Bowel Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) — 9; 5; 3; 1 Participants
Phase 2 N=174 A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
Mild Cognitive Impairment · Mild Dementia · Alzheimer's Disease
Primary: Change From Baseline in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score — 3.8; 5.3 score on a scale — p=0.1642
Phase 2 N=62 A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Primary: Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis — 25.6; -9.8; -0.6 International units/Liter — p=0.434
Phase 2 N=11 Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
Parkinsonian Signs in Older Persons
Primary: Average Gait Speed — 0.97; 0.86; 1.04; 0.95 meters per second
Phase 2 N=12 A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Tinea Pedis
Primary: Safety Evaluation Cohort 1 — 8; 0; 0; 0 Feet
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Phase 2 N=12 Gene Therapy for Painful Diabetic Neuropathy
Painful Diabetic Peripheral Neuropathy
Primary: Treatment-emergent Adverse Events for Participants Who Received Engensis 4 mg, 8 mg, or 16 mg — 3; 2; 2; 1 Participants
Phase 2 N=129 Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
Acute Bacterial Conjunctivitis
Primary: Clinical Cure Rate — 37; 31; 27; 33 Participants — p=0.0137
Phase 2 N=41 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Phase 2 N=256 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Neoplasms
Primary: Number of Participants Randomized Across Sub-studies — 105; 8; 62 Participants
Phase 2 N=44 Enhancing the Effects of Alcohol Treatment With Lamotrigine
Alcohol Use Disorder
Primary: Completion Rates — 22; 19 Participants
Phase 2 N=50 Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
Smoking Cessation
Primary: Percentage of Participants With a Continuous Smoking Abstinence Rate — 0 percentage of participants
Phase 2 N=91 High Dose IMVAMUNE® in Vaccinia-Naive Individuals
Smallpox
Primary: Time to Seroconversion After One Vaccination Using Bavarian Nordic's (BN) Enzyme Linked Immunosorbent Assay (ELISA) in the Intent-to-Treat (ITT) Population — 14; 14 days